Cytokinetics Presents New Data in Patients With

Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and...

Related Keywords

Prague ,Praha ,Hlavníesto ,Czech Republic ,Oregon ,United States ,China ,Ahmad Masri ,Fadyi Malik ,Diane Weiser ,Research Development ,Cytokinetics Incorporated Nasdaq ,Twitter ,National Medical Products Administration ,Youtube ,Linkedin ,International Congress ,European Society Of Cardiology ,Exchange Commission ,Facebook ,York Heart Association ,Us Food Drug Administration ,Corporate Communications ,Statistically Significant Improvements ,Angina Frequency ,High Sensitivity Troponin ,Randomized Evaluation ,Dosing With ,Obstructive Outflow Disease ,Late Breaking Clinical Trial ,Heart Failure ,European Society ,Cytokinetic Executive Vice President ,Hypertrophic Cardiomyopathy Center ,Oregon Health ,Science University ,Kansas City Cardiomyopathy Questionnaire ,Clinical Symptom Score ,New York Heart Association ,Breakthrough Therapy Designation ,Drug Administration ,Private Securities Litigation Reform Act ,Safe Harbor ,Vice President ,Nasdaq Cytk ,Cytokinetics ,Ncorporated ,